Inventor · disambiguated record
Jian Lin
Also filed as: LIN JIAN · LIN JIAN-SIN
44 granted patents·27 pending applications·537 citations·filing 2001–2023
98Inventor score
Top patents by PatentIndex Score
71 records- 0198US10550098B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·17 cites·25 claims
- 0298US10414752B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·19 cites·20 claims
- 0398US9834539B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Dec 5, 2017·28 cites·108 claims
- 0498US9624175B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·25 cites·39 claims
- 0598US9624216B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·26 cites·74 claims
- 0697US11498913B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2020·Granted Nov 15, 2022·4 cites·18 claims
- 0797US9771349B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 26, 2017·27 cites·68 claims
- 0896US10005734B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Jun 26, 2018·25 cites·75 claims
- 0996US9815817B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Nov 14, 2017·24 cites·48 claims
- 1095US10889567B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Jan 12, 2021·5 cites·21 claims
- 1195US10772874B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2019·Granted Sep 15, 2020·6 cites·11 claims
- 1295US10280150B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2017·Granted May 7, 2019·19 cites·2 claims
- 1395US10266495B2Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2018·Granted Apr 23, 2019·19 cites·9 claims
- 1495US10253015B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2018·Granted Apr 9, 2019·20 cites·12 claims
- 1594US10294206B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2015·Granted May 21, 2019·7 cites·16 claims
- 1694US9676721B2Compounds and compositions for the inhibition of NAMPTBAIR KENNETH W·Filed 2011·Granted Jun 13, 2017·33 cites·7 claims
- 1793US10647695B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2019·Granted May 12, 2020·5 cites·7 claims
- 1893US10272072B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2016·Granted Apr 30, 2019·11 cites·19 claims
- 1992US10577329B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Mar 3, 2020·4 cites·20 claims
- 2092US9169209B2Compounds and compositions for the inhibition of NAMPTBAIR KENNETH W·Filed 2011·Granted Oct 27, 2015·25 cites·22 claims
- 2191US11547701B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2020·Granted Jan 10, 2023·2 cites·11 claims
- 2291US11279687B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·2 cites·9 claims
- 2391US10456382B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2018·Granted Oct 29, 2019·7 cites·20 claims
- 2491US10407419B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 10, 2019·5 cites·5 claims
- 2591US10329275B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2018·Granted Jun 25, 2019·8 cites·10 claims
- 2691US7217794B2Compounds and methods for treatment of thrombosisDAIAMED INC·Filed 2004·Granted May 15, 2007·91 cites·6 claims
- 2790US9555039B2Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)BAIR KENNETH W·Filed 2011·Granted Jan 31, 2017·13 cites·19 claims
- 2888US10550099B2Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·4 cites·15 claims
- 2988US7919519B2S1P receptor modulating compounds and use thereofEPIX PHARM INC·Filed 2007·Granted Apr 5, 2011·14 cites·8 claims
- 3087US12275715B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2023·Granted Apr 15, 2025·0 cites·23 claims
- 3187US10807976B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Oct 20, 2020·2 cites·18 claims
- 3287US7501404B2Substituted azetidinonesDAIMED·Filed 2006·Granted Mar 10, 2009·21 cites·17 claims
- 3385US11479564B2Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)VALO HEALTH INC·Filed 2020·Granted Oct 25, 2022·1 cites·7 claims
- 3483US12336981B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2022·Granted Jun 24, 2025·0 cites·11 claims
- 3583US10399980B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 3, 2019·2 cites·11 claims
- 3683US10189841B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Jan 29, 2019·3 cites·11 claims
- 3783US2023125739A1Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3882US11566013B1Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)FORMA THERAPEUTICS INC·Filed 2020·Granted Jan 31, 2023·1 cites·20 claims
- 3981US11161848B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 2, 2021·1 cites·26 claims
- 4081US10696692B2Amido-benzyl sulfone and sulfoxide derivatesFORMA TM LLC·Filed 2013·Granted Jun 30, 2020·6 cites·4 claims
- 4178US2023110003A1Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)VALO HEALTH INC·Filed 2022·Application pending·0 cites
- 4277US7855193B2S1P receptor modulating compounds and use thereofEPIX PHARM INC·Filed 2006·Granted Dec 21, 2010·3 cites·11 claims
- 4376US7790707B2S1P receptor modulating compounds and use thereofEPIX PHARM INC·Filed 2007·Granted Sep 7, 2010·2 cites·11 claims
- 4475US12043623B2Purinones as ubiquitin-specific protease 1 inhibitorsFORMA THERAPEUTICS INC·Filed 2021·Granted Jul 23, 2024·0 cites·20 claims
- 4571US12122778B2Activating pyruvate kinase RNOVO NORDISK HEALTHCARE AG·Filed 2019·Granted Oct 22, 2024·0 cites·19 claims
- 4671US2020115343A1Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4765US2017174658A1Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4861US2019210995A1Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitorsFORMA TM2 INC·Filed 2018·Application pending·0 cites
- 4961US2009143351A1Substituted azetidinonesDAIAMED·Filed 2009·Application pending·0 cites
- 5061US2019031686A1Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)FORMA TM LLC·Filed 2018·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jian Lin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →